124 related articles for article (PubMed ID: 15656039)
1. In-vitro activity of linezolid against clinical isolates of Gram-positive cocci in a tertiary care hospital.
Navaneeth BV; Belwadi SM; Indumathi VA; Gayathri DD
J Assoc Physicians India; 2004 May; 52():429-30. PubMed ID: 15656039
[No Abstract] [Full Text] [Related]
2. Activity of linezolid against Gram-positive cocci: a multicentre study in Greek hospitals.
Pratti A; Karanika M; Maniatis AN; Petinaki E; Spiliopoulou I; Kolonitsiou F; Tatsiopoulos A; Alexiou-Daniel S; Bakola D; Koutsia-Carousou Ch; Malamou-Lada H; Siafakas N; Zerva L
Int J Antimicrob Agents; 2007 May; 29(5):604-5. PubMed ID: 17293090
[No Abstract] [Full Text] [Related]
3. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
Ross JE; Anderegg TR; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 May; 52(1):53-8. PubMed ID: 15878443
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of linezolid resistance in Germany, 2001-2002.
Brauers J; Kresken M; Hafner D; Shah PM;
Clin Microbiol Infect; 2005 Jan; 11(1):39-46. PubMed ID: 15649302
[TBL] [Abstract][Full Text] [Related]
5. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
Jones RN; Ross JE; Fritsche TR; Sader HS
J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
[TBL] [Abstract][Full Text] [Related]
6. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
[TBL] [Abstract][Full Text] [Related]
7. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
8. Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program.
Biedenbach DJ; Farrell DJ; Mendes RE; Ross JE; Jones RN
Diagn Microbiol Infect Dis; 2010 Dec; 68(4):459-67. PubMed ID: 21094428
[TBL] [Abstract][Full Text] [Related]
9. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
Anderegg TR; Sader HS; Fritsche TR; Ross JE; Jones RN
Int J Antimicrob Agents; 2005 Jul; 26(1):13-21. PubMed ID: 15967640
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility of staphylococci to linezolid and other antimicrobial agents.
Poiată A; Tuchiluş C; Bădicuţ I; Grigore L; Buiuc D
Roum Arch Microbiol Immunol; 2002; 61(4):293-9. PubMed ID: 15055263
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.
Yoon EJ; Jo YW; Choi SH; Lee TH; Rhee JK; Yoo M; Shim MJ; Choi EC
Antimicrob Agents Chemother; 2005 Jun; 49(6):2498-500. PubMed ID: 15917554
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of linezolid against clinical isolates of methicillin resistant Staphylococcus.
Hannan A; Absar M; Usman M; Naeem T; Saleem S; Arshad M
J Ayub Med Coll Abbottabad; 2009; 21(1):106-9. PubMed ID: 20364755
[TBL] [Abstract][Full Text] [Related]
13. Linezolid in vitro: mechanism and antibacterial spectrum.
Livermore DM
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii9-16. PubMed ID: 12730138
[TBL] [Abstract][Full Text] [Related]
14. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid.
Wareham DW; Abbas H; Karcher AM; Das SS
J Infect; 2006 Apr; 52(4):300-4. PubMed ID: 16099052
[TBL] [Abstract][Full Text] [Related]
15. Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12).
Mendes RE; Hogan PA; Streit JM; Jones RN; Flamm RK
J Antimicrob Chemother; 2014 Jun; 69(6):1582-8. PubMed ID: 24468866
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia.
Wiederhold NP; Coyle EA; Raad II; Prince RA; Lewis RE
J Antimicrob Chemother; 2005 May; 55(5):792-5. PubMed ID: 15814598
[TBL] [Abstract][Full Text] [Related]
17. First report of the activity of linezolid against Portuguese enterococci from human, animal and environmental sources.
Novais C; Sousa JC; Coque TM; Peixe LV;
J Antimicrob Chemother; 2003 May; 51(5):1314-5. PubMed ID: 12697650
[No Abstract] [Full Text] [Related]
18. In vitro activity of linezolid against Gram-positive cocci isolated in Poland.
Szczypa K; Betlejewska K; Nowak K; Hryniewicz K
J Antimicrob Chemother; 2001 Dec; 48(6):932-5. PubMed ID: 11733485
[No Abstract] [Full Text] [Related]
19. Oxazolidinones--a new class of broad-spectrum chemotherapeutics.
Sztanke K; Pasternak K; Sztanke M
Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):335-41. PubMed ID: 16146103
[TBL] [Abstract][Full Text] [Related]
20. [Linezolid--novel antibiotic for the treatment of gram-positive bacterial infections].
Jankowski A; Stefanik W
Wiad Lek; 2006; 59(9-10):727-31. PubMed ID: 17338140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
